

Dr Michael S Rose
CTL

P/2/1.16

Miss A Waring
CTL

COMPANY SECRET

MSR/JFM

Redacted - EU PII

18 Sep 78

Re: Emetic Formulation and ICI New Zealand

The emetic formulation of paraquat has now been registered in the UK and many Western European Countries. However, in order to register the new formulation in the USA and Japan, it will be necessary to provide some evidence that the product is safer in this form. Moreover, the present registration of the product in these two countries is "threatened" by toxicological considerations, particularly its use as a suicide agent. If the registration in the USA and Japan were to be withdrawn, the consequences to the Company would be very serious and the remaining markets in the rest of the world would be threatened.

I give you this background since the introduction of the new formulation in the small island of Western Samoa was seen as a way of obtaining information on the safety of the product relatively quickly. However, our data gathering has been less than satisfactory and attempts to obtain urine samples and case histories has been hampered by what appears to be a lack of commitment and a parochial attitude by ICI New Zealand that "this is our patch and we do not want ICI Australia and PPD/CTL people trampling all over it". Whilst recognising that ICI New Zealand fear that we might upset the locals (who have to be handled very carefully) I am concerned that they do not fully understand the need for the ICI Group to obtain as much information as possible, as quickly as possible.

Michael S Rose (Dr)
(dictated, not signed)